Low brain metabolism as measured from ¹⁸F-FDG PETCT is associated with higher mortality in patients with advanced non–small cell lung cancer (NSCLC), according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating brain ¹⁸F-FDG uptake alongside clinical, tumour, and biological data improved prediction of overall survival, providing physicians with valuable […]
Read MoreA noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating this new approach to DNA profiling into clinical practice has the potential […]
Read MoreA novel radiopharmaceutical therapy approach that targets fibroblast activation protein (FAP)—which is highly expressed on many types of cancers—is safe and effective for patients, according to a new study published in the June issue of The Journal of Nuclear Medicine. In a study of nearly 90 patients with 21 different types of cancer, FAP-targeted radiopharmaceutical therapy […]
Read More